Qinghai Spring Medicinal Resources Technology Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Qinghai Spring Medicinal Resources Technology's earnings have been declining at an average annual rate of -22.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.9% per year.
Wichtige Informationen
-22.4%
Wachstumsrate der Gewinne
-22.7%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 10.9% |
Wachstumsrate der Einnahmen | 5.9% |
Eigenkapitalrendite | -25.0% |
Netto-Marge | -114.6% |
Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Jun 24Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 26% Cheaper Price Remains In Tune With Revenues
May 09Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 27% Price Boost Is Out Of Tune With Revenues
Mar 12Aufschlüsselung der Einnahmen und Ausgaben
Wie Qinghai Spring Medicinal Resources Technology Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Sep 24 | 251 | -288 | 227 | 15 |
30 Jun 24 | 245 | -277 | 232 | 15 |
31 Mar 24 | 242 | -266 | 239 | 11 |
31 Dec 23 | 214 | -268 | 234 | 12 |
30 Sep 23 | 192 | -282 | 231 | 12 |
30 Jun 23 | 162 | -289 | 217 | 12 |
31 Mar 23 | 141 | -293 | 213 | 12 |
31 Dec 22 | 160 | -288 | 215 | 11 |
30 Sep 22 | 175 | -264 | 242 | 10 |
30 Jun 22 | 186 | -248 | 224 | 8 |
31 Mar 22 | 183 | -263 | 224 | 9 |
31 Dec 21 | 128 | -249 | 177 | 10 |
30 Sep 21 | 143 | -276 | 124 | 10 |
30 Jun 21 | 138 | -305 | 138 | 14 |
31 Mar 21 | 132 | -311 | 127 | 13 |
31 Dec 20 | 124 | -320 | 131 | 12 |
30 Sep 20 | 128 | -69 | 108 | 11 |
30 Jun 20 | 135 | -61 | 117 | 5 |
31 Mar 20 | 174 | -20 | 114 | 5 |
31 Dec 19 | 234 | 6 | 116 | 4 |
30 Sep 19 | 248 | -25 | 153 | 6 |
30 Jun 19 | 277 | -11 | 158 | 4 |
31 Mar 19 | 305 | 33 | 160 | 3 |
31 Dec 18 | 333 | 68 | 147 | 3 |
30 Sep 18 | 358 | 186 | 103 | 1 |
30 Jun 18 | 441 | 309 | 69 | 3 |
31 Mar 18 | 452 | 316 | 54 | 2 |
31 Dec 17 | 471 | 311 | 59 | 2 |
30 Sep 17 | 646 | 346 | 56 | 1 |
30 Jun 17 | 671 | 275 | 72 | 0 |
31 Mar 17 | 705 | 260 | 93 | 0 |
31 Dec 16 | 708 | 245 | 116 | 0 |
30 Sep 16 | 876 | 255 | 153 | 0 |
30 Jun 16 | 1,115 | 352 | 167 | 0 |
31 Mar 16 | 1,187 | 365 | 182 | 0 |
31 Dec 15 | 1,402 | 358 | 282 | 0 |
30 Sep 15 | 1,466 | 242 | 415 | 0 |
30 Jun 15 | 1,527 | 225 | 440 | 0 |
31 Mar 15 | 1,844 | 285 | 508 | 0 |
31 Dec 14 | 2,063 | 365 | 510 | 0 |
31 Dec 13 | 2,141 | 337 | 542 | 0 |
Qualität der Erträge: 600381 is currently unprofitable.
Wachsende Gewinnspanne: 600381 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 600381 is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Beschleunigtes Wachstum: Unable to compare 600381's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 600381 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 600381 has a negative Return on Equity (-25%), as it is currently unprofitable.